戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 obustness of the vaccine approval system and postmarketing surveillance.
2 se complications will likely require careful postmarketing surveillance.
3 reported to Merck, the manufacturer, through postmarketing surveillance.
4           However, few data are available on postmarketing surveillance.
5  and reinforce the critical need for ongoing postmarketing surveillance.
6 s for transcatheter aortic valve replacement postmarketing surveillance.
7 entiary regulatory standards, development of postmarketing surveillance, a focus on clinically meanin
8                                    Proactive postmarketing surveillance and further studies are pivot
9 lestra (sucrose polyester) called for active postmarketing surveillance because preapproval studies s
10               The ASRS TSC encourages active postmarketing surveillance by all physicians.
11  data submitted to Merck from routine global postmarketing surveillance, combined with information fr
12                                              Postmarketing surveillance data would be useful in asses
13 r examining the available literature and the postmarketing surveillance data, proposed a clinically b
14                              On the basis of postmarketing surveillance data, the Food and Drug Admin
15  in prescribing this drug pending additional postmarketing surveillance data.
16                       Examination of the FDA postmarketing surveillance databases revealed a low repo
17                               Using 2 global postmarketing surveillance databases, Goldman and collea
18      Longer-term clinical trials and careful postmarketing surveillance during the next several decad
19 e US Food and Drug Association (FDA), little postmarketing surveillance exists to assess real-world r
20                                      Careful postmarketing surveillance for adverse effects, especial
21 f monitoring both pharmaceutical quality and postmarketing surveillance for adverse events.
22  these issues, data from clinical trials and postmarketing surveillance have been evaluated extensive
23  recent studies have examined how frequently postmarketing surveillance identifies important ADRs.
24                                              Postmarketing surveillance indicates that the diversion
25    The most common source of safety data was postmarketing surveillance (n = 28 of 58 [48%]).
26 tinue through clinical trials, and extend to postmarketing surveillance of ADRs in real-world populat
27       However, longer-term trial results and postmarketing surveillance of major adverse events will
28 ovigilance databases are essential tools for postmarketing surveillance of medical products.
29 ition, observational studies can be used for postmarketing surveillance of new cancer treatments, par
30 ing and documenting adverse effects; and (8) postmarketing surveillance of therapy outcomes.
31                                   Additional postmarketing surveillance of these and other serious ad
32  (VAERS) is the passive reporting system for postmarketing surveillance of vaccine safety in the Unit
33 ministration mandated that companies conduct postmarketing surveillance (PMS) studies of approved ste
34 fety issues were identified through existing postmarketing surveillance programs and were of limited
35                                              Postmarketing surveillance revealed a potential serious
36                                Strengthening postmarketing surveillance strategies and pivotal trials
37 and the importance of internationally robust postmarketing surveillance strategies as crucial compone
38 n the near future, with a call for effective postmarketing surveillance studies for all of the new en
39 le, coming from either controlled trials and postmarketing surveillance studies.
40                                  This active postmarketing surveillance study of a food additive sugg
41                                         This postmarketing surveillance study was conducted to fulfil
42 that the agency's drug review procedures and postmarketing surveillance system after a drug has been
43  Administration (FDA) is building a national postmarketing surveillance system for medical devices, m
44  limited premarketing data are balanced with postmarketing surveillance to capture rare adverse event
45  This study demonstrates the power of active postmarketing surveillance to identify or exclude events
46  authorisation procedures mandated increased postmarketing surveillance to monitor vaccine safety.
47 es as applied to preclinical drug safety and postmarketing surveillance with a specific focus on mach